Download PDF
Planta Med 2004; 70(7): 685-687
DOI: 10.1055/s-2004-827196
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Antimicrobial Activities of Hydrophobic 2-Arylbenzofurans and an Isoflavone against Vancomycin-Resistant Enterococci and Methicillin-Resistant Staphylococcus aureus

Toshio Fukai1 , Yukio Oku2 , Yoshio Hano1 , Sumio Terada2
  • 1Department of Biophysical Chemistry, School of Pharmaceutical Sciences, Toho University, Chiba, Japan
  • 2Department of Natural Products, Research Laboratory, Zenyaku Kogyo Co., Ltd., Tokyo, Japan
Further Information

Publication History

Received: December 10, 2003

Accepted: April 24, 2004

Publication Date:
15 July 2004 (online)

    Permissions and Reprints

Abstract

Eight 2-arylbenzofurans and an isoflavone isolated from medicinal plants were tested for their antimicrobial activities against vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Among these compounds, six hydrophobic 2-arylbenzofurans (log P = 4.4 - 8.7) exhibited considerable antibacterial activity against five VRE strains (VanA-, VanB-, and VanC-phenotypes) (MICs = 3.13 - 6.25 μg/mL). Five compounds also showed antibacterial activity against ten MRSA strains (MIC80 = 3.13 μg/mL).

References

  • 1 Borgen K, Sorum M, Wasteson Y, Kruse H. VanA-type vancomycin-resistant enterococci (VRE) remain prevalent in poultry carcasses 3 years after avoparcin was banned.  Int J Food Microbiol. 2001;  64 89-94
    CrossrefPubMedGoogle Scholar
  • 2 Casewell M, Friis C, Marco E, McMullin P, Phillips I. The European ban on growth-promoting antibiotics and emerging consequences for human and animal health.  J Anrimicrob Chemother. 2003;  52 159-61
    PubMedGoogle Scholar
  • 3 Patel R. Clinical impact of vancomycin-resistant enterococci.  J Antimicrob Chemother. 2003;  51 III13-21
    PubMedGoogle Scholar
  • 4 Kauffman C A. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections.  J Antimicrob Chemother. 2003;  51 III23-30
    PubMedGoogle Scholar
  • 5 Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T. Antimicrobial activity of licorice flavonoids against methicillin-resistant Staphylococcus aureus .  Fitoterapia. 2002;  73 536-9
    CrossrefPubMedGoogle Scholar
  • 6 Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T. Anti-Helicobacter pylori flavonoids from licorice extract.  Life Sci. 2002;  71 1449-63
    CrossrefPubMedGoogle Scholar
  • 7 Shi Y -Q, Fukai T, Sakagami H, Chang W -J, Yang P -Q, Wang F -P, Nomura T. Cytotoxic flavonoids with isoprenoid groups from Morus mongolica .  J Nat Prod. 2001;  64 181-8
    CrossrefPubMedGoogle Scholar
  • 8 a) Fukai T, Hano Y, Hirakura K, Nomura T, Uzawa J, Fukushima K. Constituents of the cultivated mulberry tree. 25. Structures of two natural hypotensive Diels-Alder type adducts, mulberrofurans F and G, from the cultivated mulberry tree (Morus lhou Koidz.)  Chem Pharm Bull. 1985;  33 3195-204; b) Hano Y, Miyagawa Y, Yano M, Nomura T. Correlation between albanol B and mulberrofuran I, and structure of mulberrofuran S, novel 2-arylbenzofu
    PubMedGoogle Scholar
  • 9 Shimazaki M, Hano Y, Nomura T. Studies on Morus bombycis callus cultures.  Natural Medicines (Tokyo). 2000;  54 346-9
    PubMedGoogle Scholar
  • 10 Salvatore M J, King A B, Graham A C, Onishi H R, Bartizal K F, Abruzzo G K. et al . Antibacterial activity of lonchocarpol A.  J Nat Prod. 1998;  61 640-2
    CrossrefPubMedGoogle Scholar
  • 11 Tanaka H, Sato M, Fujiwara S, Hirata M, Etoh H, Takeuchi H. Antibacterial activity of isoflavonoids isolated from Erythrina variegata against methicillin-resistant Staphylococcus aureus .  Lett Appl Microbiol. 2002;  35 494-8
    CrossrefPubMedGoogle Scholar
  • 12 Hori S. Hospital infection control measures for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.  Nippon Rinsho. 2002;  60 2144-9
    PubMedGoogle Scholar
  • 13 Fukai T, Pei Y -H, Nomura T, Xu C -Q, Wu L -J, Chen Y -J. Components of the root bark of Morus cathayana. 1. Structures of five new isoprenylated flavonoids, sanggenols A - E and a diprenyl-2-arylbenzofuran, mulberrofuran V.  Heterocycles. 1996;  43 425-36
    PubMedGoogle Scholar
  • 14 Japan Society of Chemotherapy Working P arty. Re-revised assay method of minimum inhibitory concentration.  Chemotherapy. 1981;  29 76-9
    PubMedGoogle Scholar
  • 15 Zhanel G G, Laing N M, Nichol K A, Palatnick L P, Noreddin A, Hisanaga T, Johnson J L, Hoban D J, and the NAVRESS G roup. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS).  J Antimicrob Chemother. 2003;  52 382-8
    CrossrefPubMedGoogle Scholar
  • 16 Wunderink R G, Rello J, Cammarata S K, Croos-Dabrera R V, Kollef M H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.  Chest. 2003;  124 1789-97
    CrossrefPubMedGoogle Scholar

Dr. Toshio Fukai

Department of Biophysical Chemistry

School of Pharmaceutical Sciences

Toho University

2-2-1 Miyama

Funabashi

Chiba 274-8510

Japan

Fax: +81-47-476-6195

Email: fukai@phar.toho-u.ac.jp

      >